asciminib

Asciminib is a small molecule tyrosine kinase inhibitor used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase, including patients who are newly diagnosed, those previously treated with two or more tyrosine kinase inhibitors (TKIs), and those with the T315I mutation. Unlike other TKIs that bind to the ATP-binding site of BCR-ABL1, asciminib uniquely acts as an allosteric inhibitor by binding to the myristoyl pocket of the BCR-ABL1 fusion protein, locking it into an inactive conformation. This mechanism allows it to overcome resistance seen with other TKIs and target both wild-type and mutant forms (including T315I) of BCR-ABL1. Asciminib was developed by Novartis and is marketed under the brand name Scemblix[2][4][6][8].

Brand names

Scemblix

Other names

asciminib hydrochloride